Wells Fargo lowered the firm’s price target on PTC Therapeutics (PTCT) to $73 from $79 and keeps an Overweight rating on the shares. Expectations for Friedreich’s ataxia were “limited” following comments suggesting PTC was not in labeling discussions for vatiquinone in early August, and the complete response letter appears to be a clearing event, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target lowered to $63 from $64 at Jefferies
- RBC says PTC Therapeutics CRL may signal difficulty for Biohaven
- PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital
- PTC Therapeutics: Buy Rating Maintained Despite Vatiquinone Setback
- PTC Therapeutics price target lowered to $50 from $56 at TD Cowen